MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE: COV, BSX: COV) today announced that it fully endorses the recent updates to the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals and that its pharmaceutical businesses will comply with all aspects of the revised Code.
